DEA’s ruling leaves researchers divided


The United States may soon enter into a new era of medicine, after the Drug Enforcement Administration vowed last week to make it easier for researchers and private companies to grow or obtain marijuana for study. “If things work as they should, this will be the first day of a cannabinoid pharmaceutical industry,” says Robert Sievers, a chemistry professor at the University of Colorado who studies cannabinoids. That’s the optimistic view, at least. But the DEA decision to keep marijuana in the most restricted class of controlled substances leaves significant hurdles in place for researchers hoping to study cannabis. And, because of that, some scientists are uncertain about how much actually will change. Full Article – The Cannabist